Provided by Tiger Fintech (Singapore) Pte. Ltd.

MediWound

19.27
-0.0700-0.36%
Post-market: 19.270.00000.00%16:04 EDT
Volume:46.51K
Turnover:897.82K
Market Cap:208.26M
PE:-9.37
High:19.55
Open:19.30
Low:19.11
Close:19.34
Loading ...

Mediwound Ltd expected to post a loss of 61 cents a share - Earnings Preview

Reuters
·
17 Mar

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
03 Mar

MediWound Initiated at Buy by Craig-Hallum

Dow Jones
·
28 Feb

Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

GlobeNewswire
·
25 Feb

MediWound Launches Phase III Trial Evaluating EscharEx for Treating Venous Leg Ulcers

MT Newswires Live
·
12 Feb

MediWound Launches Phase III Trial for EscharEx Targeting Venous Leg Ulcers

TIPRANKS
·
12 Feb

Mediwound Ltd - Interim Analysis Expected in Mid-2026 After 65% Patients Complete Treatment

THOMSON REUTERS
·
12 Feb

Mediwound Ltd - Preparing Phase Ii/Iii Trial for Dfus Expected to Begin in 2026

THOMSON REUTERS
·
12 Feb

Mediwound Initiates the Value Global Phase Iii Pivotal Trial of Escharex® for Treatment of Venous Leg Ulcers

THOMSON REUTERS
·
12 Feb

Mediwound Ltd - to Initiate Phase Ii Study Comparing Escharex to Collagenase in 2025

THOMSON REUTERS
·
12 Feb

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

GlobeNewswire
·
12 Feb

MediWound Ltd.'s (NASDAQ:MDWD) high institutional ownership speaks for itself as stock continues to impress, up 15% over last week

Simply Wall St.
·
28 Jan

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

Zacks
·
27 Jan

Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Mediwound (MDWD)

TIPRANKS
·
14 Jan

Buy Rating for Mediwound Driven by EscharEx’s Market Potential and Disruptive Role in Chronic Wound Care

TIPRANKS
·
12 Jan

MediWound Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Buy Rating for Mediwound Driven by EscharEx’s Promising Market Potential and Revenue Growth

TIPRANKS
·
10 Jan

Mediwound (MDWD) Receives a Buy from TD Cowen

TIPRANKS
·
09 Jan

Mediwound Advances in Enzymatic Therapeutics with Strategic Expansions

TIPRANKS
·
08 Jan